Neurotoxic effects of ivermectin administration in genetically engineered mice with targeted insertion of the mutated canine ABCB1 gene

American Journal of Veterinary Research

Volumn 73, Issue 9, 2012, Pages 1477-1484

  Orzechowski, Krystyna L ^a   Swain, Marla D ^a   Robl, Martin G ^a   Tinaza, Constante A ^a   Swaim, Heidi L ^a   Jones, Yolanda L ^a   Myers, Michael J ^a   Yancy, Haile F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCEROL; GLYCOPROTEIN P; IVERMECTIN; PROPYLENE GLYCOL;

ABCB1 GENE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATAXIA; C57BL 6 MOUSE; CONTROLLED STUDY; COORDINATION DISORDER; DISORIENTATION; DOG; DRUG SENSITIVITY; FEMALE; GENE; GENE DISRUPTION; GENE INSERTION; GENE MUTATION; LETHARGY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING; STUPOR; TRANSGENIC MOUSE; TREMOR; WILD TYPE;

ANIMALS; ANTHELMINTICS; ATAXIA; DOG DISEASES; DOGS; FRAMESHIFT MUTATION; GENOTYPE; INJECTIONS, SUBCUTANEOUS; IVERMECTIN; LETHARGY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROTOXICITY SYNDROMES; P-GLYCOPROTEIN; REAL-TIME POLYMERASE CHAIN REACTION; RNA; TREMOR;

ANIMALIA; CANIS FAMILIARIS; MUS; MUS MUSCULUS;

EID: 84865796287     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.9.1477     Document Type: Article

References (37)

1. Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-1302.
2. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006;25:231-259.
3. Fecht S, Distl O. Review of prevalence, genetic aspects and adverse effects of the mdr1-1Delta mutation in dogs. Dtsch Tierarztl Wochenschr 2008;115:212-219.
4. Kim IW, Booth-Genthe C, Ambudkar SV. Relationship between drugs and functional activity of various mammalian P-glycoproteins (ABCB1). Mini Rev Med Chem 2008;8:193-200.
5. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002;34:47-54.
6. Mealey KL. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 2004;27:257-264.
7. Mealey KL, Bentjen SA, Gay JM, et al. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001;11:727-733.
8. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites. Proc Natl Acad Sci U S A 1989;86:695-698.
9. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997;8:161-170.
10. Schinkel AH. Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther 1998;36:9-13.
11. Paul AJ, Tranquilli WJ, Seward RL, et al. Clinical observations in collies given ivermectin orally. Am J Vet Res 1987;48:684-685.
12. Pulliam JD, Seward RL, Henry RT, et al. Investigating ivermectin toxicity in Collies. Vet Med 1985;80:33-40.
13. Baars C, Leeb T, von Klopmann T, et al. Allele-specific polymerase chain reaction diagnostic test for the functional MDR1 polymorphism in dogs. Vet J 2008;177:394-397.
14. Kawabata A, Momoi Y, Inoue-Murayama M, et al. Canine mdr1 gene mutation in Japan. J Vet Med Sci 2005;67:1103-1107.
15. Neff MW, Robertson KR, Wong AK, et al. Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci U S A 2004;101:11725-11730.
16. Roulet A, Puel O, Gesta S, et al. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 2003;460:85-91.
17. Gramer I, Leidolf R, Doring B, et al. Breed distribution of the nt230(del4) MDR1 mutation in dogs. Vet J 2011;189:67-71.
18. Mealey KL, Northrup NC, Bentjen SA. Increased toxicity of Pglycoprotein- substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc 2003;223:1453-1455.
19. Borst P, Schinkel AH. What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer 1996;32:985-990.
20. Croop JM, Raymond M, Haber D, et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989;9:1346-1350.
21. Cui YJ, Cheng X, Weaver YM, et al. Tissue distribution, genderdivergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. Drug Metab Dispos 2009;37:203-210.
22. Schinkel AH, Mol CA, Wagenaar E, et al. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995;31:1295-1298.
23. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502.
24. DeGorter MK, Kim RB. Use of transgenic and knockout mouse models to assess solute carrier transporter function. Clin Pharmacol Ther 2011;89:612-616.
25. Canard G, Hardy P, Veillet F. Micobiological validation of the "M.I.C.E." caging system. Available at: www.criver.com/SiteCollectionDocuments/eq_r_mice_caging_system_microbiological_validation.pdf. Accessed Aug 26, 2011.
26. Golde WT, Gollobin P, Rodriguez LL. A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Anim (N Y) 2005;34:39-43.
27. Dadarkar SS, Deore MD, Gatne MM. Comparative evaluation of acute toxicity of ivermectin by two methods after single subcutaneous administration in rats. Regul Toxicol Pharmacol 2007;47:257-260.
28. Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectininduced neurotoxicity. Toxicol Appl Pharmacol 1997;143:357-365.
29. Kahn CM, Line S, eds. The Merck veterinary manual. 10th ed. Whitehouse Station, NJ: Merck & Co Inc, 2010.
30. Kumar S, Porcu P, Werner DF, et al. The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progress. Psychopharmacology (Berl) 2009;205:529-564.
31. Majchrowicz E. Induction of physical dependence upon ethanol and the associated behavioral changes in rats. Psychopharmacologia 1975;43:245-254.
32. Metten P, Best KL, Cameron AJ, et al. Observer-rated ataxia: rating scales for assessment of genetic differences in ethanolinduced intoxication in mice. J Appl Physiol 2004;97:360-368.
33. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997;94:4028-4033.
34. Macdonald N, Gledhill A. Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans. Arch Toxicol 2007;81:553-563.
35. Lankas GR, Minsker DH, Robertson RT. Effects of ivermectin on reproduction and neonatal toxicity in rats. Food Chem Toxicol 1989;27:523-529.
36. Fisher MH, Mrozik H. The chemistry and pharmacology of avermectins. Annu Rev Pharmacol Toxicol 1992;32:537-553.
37. McKellar QA, Benchaoui HA. Avermectins and milbemycins. J Vet Pharmacol Ther 1996;19:331-351.